Medical Oncologist
Targeted therapy
EGFR Mutation in Lung Cancer: — What It Means and How TKIs Treat It
An EGFR mutation means your lung cancer carries a specific gene change that a class of targeted drugs — tyrosine kinase inhibitors — is designed to treat. Finding this mutation changes what treatment your oncologist is likely to recommend first.
Medically reviewed by Dr. C. Raghavendra Reddy, Medical Oncologist, MBBS (Gold Medal) · DNB · DM (Medical Oncology, Gold Medal) · Last reviewed August 2026
- Your mutation is the treatment decision — A positive EGFR result usually shifts the recommended first treatment from chemotherapy to a daily oral tablet.
- More common in Indian patients — EGFR mutations occur more often in Asian populations, including patients in India, than in Western populations.
- Testing is essential first — Without biomarker testing on your tumour tissue or blood, this result — and the treatment it points to — remains invisible.
- Resistance is manageable — When a targeted drug eventually stops working, a repeat test guides what comes next. Your team plans for this from the start.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
An EGFR mutation means your lung cancer has a specific change in the EGFR gene that makes it grow uncontrolled. NCCN and ESMO recommend a targeted drug called a tyrosine kinase inhibitor — taken as a daily tablet — as the first treatment for most people with this result, rather than standard chemotherapy.
What does an EGFR mutation actually mean?
EGFR stands for Epidermal Growth Factor Receptor, a protein that tells cells when to grow. In EGFR-mutated lung cancer, a change in the gene that makes this protein keeps it permanently switched on, so cancer cells grow without a normal signal to stop.
This mutation developed in the cancer cells themselves. It is not inherited and not something you caused.
EGFR mutations are found more often in adenocarcinoma lung cancer, in people who have never smoked or smoked lightly, and in Asian populations — including patients in India. Your oncologist would have ordered this test on tissue from your biopsy or on a blood sample.
How does EGFR-targeted treatment work?
Tyrosine kinase inhibitors — TKIs — are tablets taken daily at home. They work by blocking the mutated EGFR protein, which aims to slow or stop cancer growth.
NCCN and ESMO guidance identifies osimertinib, a third-generation TKI, as the preferred starting treatment for most people with the common EGFR mutations. Your oncologist may recommend a different TKI depending on your specific mutation subtype and overall health.
Resistance can develop over time. When it does, a repeat biopsy or liquid biopsy is done to understand why, and the result guides the next step. Your team plans for this from the beginning.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Get a straight answer from a specialist
45 minutes, your reports reviewed, your questions answered in plain language.
Which EGFR-targeted drugs are available and what does each one do?
- Osimertinib — third-generation TKI
- Recommended by NCCN and ESMO as the preferred first treatment for most common EGFR mutations. It crosses into the brain more effectively than earlier TKIs, which matters when cancer has spread there. Also the standard next treatment when a T790M resistance mutation develops after an earlier TKI.
- Gefitinib — first-generation TKI
- One of the earliest targeted therapies for EGFR-mutated lung cancer and among the first approved in India. Still used in some settings depending on mutation type, regional availability, and clinical circumstances your oncologist will explain.
- Erlotinib — first-generation TKI
- Similar in mechanism to gefitinib. Used alone or in combination with other medicines for specific mutation profiles and disease stages. Some combination regimens are supported by evidence reviewed by ESMO and NCCN.
- Afatinib — second-generation TKI
- Preferred by some guidelines for certain uncommon EGFR mutations, particularly those in exon 18 and some exon 20 variants. Targets a broader range of EGFR-family proteins than first-generation drugs.
- Dacomitinib — second-generation TKI
- Another second-generation option with a similar mechanism to afatinib. Your oncologist will explain which generation is appropriate for your mutation subtype, stage, and health status.
Did you know?
EGFR mutations are found significantly more often in lung cancer patients in India and across Asia than in Western populations.
NCCN, ASCO and ESMO all recommend testing for EGFR — alongside other key mutations — before starting any treatment for non-small-cell lung cancer, because the result directly determines which treatment is offered first.
Source: ESMO Clinical Practice Guidelines for Metastatic Non-Small-Cell Lung Cancer
Explore 119 more Targeted Therapy Basics, Testing & Your Cancer Type topics
Mutation & Target-Specific Pages
- ALK-Positive Lung Cancer: Drugs, Response and What Comes Next
- Antiangiogenic Drugs (VEGF Inhibitors): How Starving a Tumour Works
- BCR-ABL and the Philadelphia Chromosome in CML
- BRAF V600E Mutation: Targeted Therapy Across Multiple Cancers
- BRCA vs HRD Testing: Which One Determines PARP Inhibitor Eligibility?
- BRCA1 and BRCA2 Mutations in Cancer Treatment: PARP Inhibitors
- BTK Inhibitors in CLL and Lymphoma
- CD20, CD38 and Other Antibody Targets in Blood Cancers
- CDK4/6 Inhibitors in Hormone-Positive Breast Cancer
- Co-Mutations: When You Have Two Mutations at Once
- EGFR Exon 20 Insertion: Why It's Different and Harder to Treat
- EGFR Mutation in Lung Cancer: Complete Patient Guide
- ESR1 Mutation: Why Your Hormone Therapy Stopped Working
- FGFR Alterations in Bladder and Bile Duct Cancer
- FLT3 Mutation in AML: What It Means for Your Prognosis
- HER2 Mutation in Lung and Gastric Cancer
- HER2-Low Breast Cancer: A New Category That Changes Treatment
- HER2-Positive Breast Cancer: The Full Targeted Therapy Roadmap
- IDH1 and IDH2 Mutations in Glioma, AML and Bile Duct Cancer
- KIT and PDGFRA Mutations in GIST
- KRAS G12C Mutation: The Target That Was Undruggable for 40 Years
- KRAS Mutation but Not G12C: What Are My Options?
- MET Exon 14 Skipping and MET Amplification Explained
- MSI-High and Mismatch Repair Deficiency: Testing and Treatment
- NRG1, MET, RET and Other Rare Fusions: Where to Get Tested
- NTRK Fusion: One Drug for Many Different Cancers
- Osimertinib: What to Expect, Side Effects and How Long It Works
- PALB2, ATM and Other BRCA-Like Genes: Do They Get the Same Drugs?
- PIK3CA Mutation in Breast Cancer: Alpelisib and What to Expect
- PSMA and AR-Targeted Therapy in Prostate Cancer
- RET Fusion Cancer: Lung, Thyroid and Beyond
- ROS1-Positive Cancer: A Rare Mutation with Excellent Options
- TP53 Mutation: Why There's Still No Targeted Drug for It
- Understanding Variant Allele Frequency (VAF) in Your Report
- What If My Mutation Has No Approved Drug Yet?
- mTOR Inhibitors in Cancer: Everolimus and Temsirolimus
Before You Start - Preparation & Baseline
- 25 Questions to Ask Your Oncologist Before Starting Targeted Therapy
- Before You Start Targeted Therapy: The Complete Preparation Checklist
- Dental Check-Up Before Cancer Treatment: Why It Matters
- Financial Planning Before Starting Long-Term Targeted Therapy
- How Long After Surgery Can You Start Targeted Therapy?
- How to Store Your Targeted Therapy Tablets Correctly
- Setting Up a Dosing Routine You Won't Forget
- Should Targeted Therapy Be Taken With Food or on an Empty Stomach?
- Vaccinations Before and During Cancer Treatment
- What to Expect in Your First Month on Targeted Therapy
- Which Baseline Tests Are Done Before Starting a TKI?
- Which of Your Existing Medicines Must Stop Before Targeted Therapy
- Why You Need an ECHO and ECG Before Certain Cancer Drugs
Biomarker & Molecular Testing
- Can Mutation Testing Be Done on an Old Biopsy Block or Slides?
- Cost of NGS and Mutation Testing in India: 2026 Price Guide
- Do I Need Genetic Testing Before Starting Targeted Therapy?
- Germline vs Somatic Testing: The Difference Nobody Explains Properly
- Getting a Second Opinion on Your Genomic Report
- How Long Do Mutation Test Results Take in India? Realistic Timelines
- How to Read Your Molecular Pathology Report, Line by Line
- IHC, FISH, PCR or NGS: Which Mutation Test Is Right for Your Cancer?
- Is Mutation Testing Worth It If I Can't Afford the Drug?
- Liquid Biopsy vs Tissue Biopsy: Which Test Do You Need?
- My Report Says a Mutation Is 'Actionable': What Does That Mean?
- No Mutation Found in My Report: What Are My Options Now?
- Should I Start Chemotherapy While Waiting for Mutation Results?
- Should You Repeat Molecular Testing After Your Cancer Progresses?
- Single-Gene Test or Full Panel? How to Choose Without Wasting Money
- What Are PD-L1, TMB and MSI, and Do They Affect Targeted Therapy?
- What Does 'Variant of Uncertain Significance' (VUS) Mean?
- What Happens If There Isn't Enough Tissue for Mutation Testing?
- What Is NGS (Next-Generation Sequencing) Testing in Cancer?
- What Is a Molecular Tumour Board and Why Should You Want One?
- Which Cancers Should Always Be Tested for Mutations? A Checklist
- ctDNA and MRD Testing: Tracking Cancer Through a Blood Test
Cancer-Type Specific Targeted Therapy
- CML Treatment with TKIs: Living a Normal Life Span
- Cancer of Unknown Primary: Can Molecular Testing Help?
- GIST Treatment: Why This Cancer Changed Targeted Therapy Forever
- Targeted Therapy for Bile Duct Cancer (Cholangiocarcinoma)
- Targeted Therapy for Bladder and Urothelial Cancer
- Targeted Therapy for Brain Tumours and Glioma
- Targeted Therapy for Breast Cancer: HER2, HR+ and Triple Negative
- Targeted Therapy for CLL and Lymphoma
- Targeted Therapy for Cervical and Endometrial Cancer
- Targeted Therapy for Childhood Cancers
- Targeted Therapy for Colorectal Cancer: RAS, BRAF and HER2
- Targeted Therapy for Head and Neck Cancer
- Targeted Therapy for Kidney Cancer (RCC)
- Targeted Therapy for Liver Cancer (HCC)
- Targeted Therapy for Lung Cancer: Every Mutation and Drug Explained
- Targeted Therapy for Melanoma: BRAF and MEK Inhibitors
- Targeted Therapy for Multiple Myeloma
- Targeted Therapy for Neuroendocrine Tumours
- Targeted Therapy for Ovarian Cancer: PARP Inhibitors and Beyond
- Targeted Therapy for Pancreatic Cancer: Limited but Real Options
- Targeted Therapy for Prostate Cancer
- Targeted Therapy for Sarcoma
- Targeted Therapy for Stomach and Gastroesophageal Cancer
- Targeted Therapy for Thyroid Cancer
- Targeted Therapy in AML: Beyond Standard Chemotherapy
- Tumour-Agnostic Drugs: When the Mutation Matters More Than the Organ
Foundations & How Targeted Therapy Works
- Adjuvant and Neoadjuvant Targeted Therapy: Treatment Before or After Surgery
- Antibody-Drug Conjugates (ADCs): The Smart Bombs of Cancer Treatment
- Biosimilars and Generic Targeted Therapy Drugs: What They Are
- Can Targeted Therapy Be Combined with Chemotherapy or Radiation?
- Can Targeted Therapy Cure Cancer? An Honest Answer
- First-Line, Second-Line and Beyond: How Treatment Lines Work
- How Doctors Decide Between Chemo, Immunotherapy and Targeted Therapy
- How Does Targeted Therapy Actually Work? Explained Without Jargon
- How Long Does Targeted Therapy Take to Start Working?
- Is Targeted Therapy Painful? What the Treatment Actually Feels Like
- Is Targeted Therapy a Type of Chemotherapy? Clearing Up the Confusion
- Oral Tablets vs IV Infusion Targeted Therapy: What's the Difference?
- Precision Oncology vs Personalised Medicine: Are They the Same Thing?
- Targeted Therapy Success Rates: What the Numbers Really Mean
- Targeted Therapy for Stage 4 Cancer: What You Can Realistically Expect
- Targeted Therapy vs Chemotherapy: 12 Differences That Actually Matter
- Targeted Therapy vs Immunotherapy: Which One Is Right for You?
- The 8 Main Types of Targeted Therapy Drugs (With Examples)
- What Do Cancer Drug Endings Like -nib, -mab and -tinib Mean?
- What Is Targeted Therapy for Cancer? A Complete Patient Guide
- Which Cancers Can Be Treated with Targeted Therapy? Full List
- Why Didn't My Doctor Recommend Targeted Therapy for Me?
Next step
Still not sure what applies to you?
Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.
Common questions
Frequently asked questions
Do I need chemotherapy if my EGFR test is positive?
For most people with a common EGFR mutation, NCCN and ESMO recommend starting with a TKI tablet rather than chemotherapy. Chemotherapy may still be part of treatment later — for example, when a TKI stops working — but it is not usually the first step. Some regimens for specific mutation subtypes do combine a TKI with chemotherapy, which your oncologist will explain if it applies to you.
Can EGFR-mutated lung cancer spread to the brain?
Yes, and this is one reason the choice of TKI matters. Osimertinib crosses the blood-brain barrier more effectively than first- and second-generation drugs, which is why it is often preferred when brain involvement is present or considered a risk. Tell your team immediately if you develop new headaches, vision changes, weakness, or balance problems — these need urgent assessment.
What is a T790M mutation and why does my doctor keep mentioning it?
T790M is the most common resistance change that appears after a first- or second-generation TKI stops working. It is a new mutation in the same EGFR gene that makes the cancer less sensitive to the original drug. A repeat biopsy or liquid biopsy detects it. If T790M is found, osimertinib is the standard recommended next treatment because it was designed specifically to target this resistance mechanism.
How long does EGFR-targeted treatment usually last?
There is no fixed answer, because response duration varies from person to person. What NCCN and ESMO evidence shows consistently is that targeted therapy aims to control the disease for an extended period, and your oncologist will monitor you with regular scans. When scans show the cancer is no longer responding, that is the planned signal that triggers the next step — your team is watching for it.
Is EGFR testing done on blood or on the tumour?
Both are possible. Testing on tumour tissue from a biopsy is the standard first approach and gives the most complete picture. A blood test — called a liquid biopsy — detects EGFR mutations from tumour DNA circulating in the bloodstream and is useful when a tissue biopsy cannot be done or when monitoring for resistance after treatment starts. Your oncologist will decide which is appropriate at each stage.
What happens when a TKI stops working?
When a routine scan shows the cancer progressing on a TKI, your oncologist will typically order a repeat tissue biopsy or liquid biopsy to understand the resistance mechanism. The result guides the next treatment — which may be a different generation TKI, a combination approach, chemotherapy, or a clinical trial. Resistance is an expected part of managing this cancer over time, and your team plans for it from the beginning.